The New Age of Regenerative Medicine : Why Stem Cell Therapy?

The New Age of Regenerative Medicine : Why Stem Cell Therapy?

  • September 2015 •
  • 60 pages •
  • Report ID: 3250972 •
  • Format: PDF
The New Age of Regenerative Medicine : Why Stem Cell Therapy?


Cell therapy is the fastest growing segment of the Regenerative Medicine (RM) industry. It comprises both immune cell therapy and stem cell therapy; however, stem cell therapy makes up the largest part of this segment. The global cell therapy market is driven by the success of stem cell treatments in treating or curing life-threatening diseases such as cancer, heart disease, and neuro-muscular ailments among the ageing population. This research study provides an overview of the regenerative medicine industry and an insight on successful stem cell therapy treatments. It also analyses marketed products, stem cell manufacturing and funding, and the collaborative partnerships in the regenerative medicine industry.

Key Findings

Regenerative Medicine (RM) represents a new human-health paradigm with the potential to resolve unmet medical needs by addressing the underlying causes of diseases.
- The global regenerative medicine industry was worth $ billion in 2013 and is expected to reach $ billion in 2020, growing at a robust Cumulative Annual Growth Rate (CAGR) of % (2013–2020).
- Globally, there are over companies focussed on regenerative medicine. The United States has the most registered RM companies, followed by the United Kingdom, Germany, and Japan. - There are over 80 public RM companies in the world with approximately $ billion of market capital.
- In the cell therapy segment, non-healing wounds and skin wounds have the highest market share ( %); this is closely followed by the musculoskeletal sector at %.
- The Asia-Pacific stem cell therapy research market was valued at $ million in 2014 and is projected to increase to $ million by 2018.
- Rapidly growing medical tourism, contract research outsourcing, and a rising population of patients with neurological and other chronic conditions are some of the factors driving the Asian stem cells market.